GW9662

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：GW9662	Purity：98% min
CAS NO：22978-25-2	Solubility：DMSO : ≥ 100 mg/mL (361.43 mM)
Molecular Formula：C₁₃H₉ClN₂O₃	Package：Package according to customer requirements
Molecular Weight：276.675	Storage：Store at -20℃

Quality control

Remarks

GW9662 is a potent, irreversible and selective PPARgamma antagonist, which prevented activation of PPARgamma and inhibited growth of human mammary tumour cell lines. GW9662 may permit use of anti-ER strategies to inhibit breast cancer in ER- patients.

Properties:
Appearance & Physical State: Off-White Solid
Density: 1.44g/cm3
Melting Point: 171-175 °C(lit.)
Boiling Point: 360.9ºC at 760mmHg
Flash Point: 172ºC
Refractive Index: 1.676
Storage Condition: 2-8°C
Vapor Pressure: 2.15E-05mmHg at 25°C

Related Prodcuts:

TAS-103; TAS-103 dihydrochloride; BRD73954; PU-WS13; L189; SCR7; Ispinesib; Dasabuvir; Ellipticine; Rucaparib; Rucaparib phosphate; Rucaparib camsylate; CB-5083; Maytansinoid DM 1; Mirin; Dasabuvir sodium; Dexrazoxane Hydrochloride; Nedaplatin; CAY10572

References

[1]. Leesnitzer LM, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry. 2002 May 28;41(21):6640-50.

[2]. Seargent JM, et al. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol. 2004 Dec;143(8):933-7.